NASDAQ · EQ
Equillium, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for EQ: Nov 12, 2026
Equillium, Inc. Common Stock is estimated to report earnings on 11/12/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 6 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.05. The reported EPS for the same quarter last year was $-0.06.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.05 | $-0.04 | $-0.06 | 6 |
| Dec 2026 | $-0.06 | $-0.05 | $-0.07 | 6 |
| Mar 2027 | $-0.06 | $-0.06 | $-0.06 | 2 |
| Jun 2027 | $-0.06 | $-0.06 | $-0.06 | 2 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · BNK Invest · MarketBeat · Fintel- RTTNews · Oct 7, 6:52 AM EDTEquillium Gains Australian Nod For Phase 1 Study Of EQ504; Dosing In Nov'26(RTTNews) – Equillium Inc. (EQ), a biotechnology company, on Tuesday announced receiving clearance from the Human Research Ethics Committee (HREC) and the Therapeutic Goods Administration (TGA) of Australia to proceed with the Phase 1 trial evaluating EQ504 in treating ulcerative
- BNK Invest · Oct 2, 2:40 PM EDTFriday Sector Laggards: Information Technology Services, DrugsIn trading on Friday, information technology services shares were relative laggards, down on the day by about 0.9%. Helping drag down the group were shares of Concentrix, off about 8.6% and shares of Digimarc down about 5.9% on the day. Also lagging the market Friday are drugs
- MarketBeat · Sep 27, 6:01 PM EDTEquillium Eyes Q4 Phase I Start for Ulcerative Colitis Drug EQ504Data Centers Got the AI Hype—But Office REITs May Get the Rent HikesEquillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined the company’s plans to advance its lead programs, including an oral aryl hydrocarbon receptor, or AhR, modulator for ulcerative colitis and
- MarketBeat · May 29, 11:03 AM EDTEquillium Links AhR Activation to miR-124 as EQ504 Heads Toward Phase 13 REITs to Watch as AI Data Center Spending Surpasses Office ConstructionEquillium (NASDAQ:EQ) Chief Scientific Officer Stephen Connelly outlined new preclinical data during a company webinar focused on the relationship between the aryl hydrocarbon receptor, or AhR, and miR-124,
- Fintel · May 28, 8:03 PM EDTLeerink Partners Upgrades Equillium (EQ)Fintel reports that on May 28, 2026, Leerink Partners upgraded their outlook for Equillium (NasdaqCM:EQ) from Market Perform to Outperform. Analyst Price Forecast Suggests 177.03% Upside
- Fintel · Apr 16, 8:05 PM EDTB. Riley Securities Initiates Coverage of Equillium (EQ) with Buy RecommendationFintel reports that on April 16, 2026, B. Riley Securities initiated coverage of Equillium (NasdaqCM:EQ) with a Buy recommendation. Analyst Price Forecast Suggests 301.27% Upside
- Fintel · Apr 14, 10:02 AM EDTEquillium (EQ) Price Target Increased by 10.71% to 7.90The average one-year price target for Equillium (NasdaqCM:EQ) has been revised to $7.90 / share. This is an increase of 10.71% from the prior estimate of $7.14 dated April 7, 2026. The price target is an average of many targets provided by analysts. The latest
- Fintel · Apr 14, 10:02 AM EDTRaymond James Initiates Coverage of Equillium (EQ) with Strong Buy RecommendationFintel reports that on April 14, 2026, Raymond James initiated coverage of Equillium (NasdaqCM:EQ) with a Strong Buy recommendation. Analyst Price Forecast Suggests 320.00% Upside
- Fintel · Apr 9, 7:03 AM EDTEquillium (EQ) Price Target Increased by 27.27% to 7.14The average one-year price target for Equillium (NasdaqCM:EQ) has been revised to $7.14 / share. This is an increase of 27.27% from the prior estimate of $5.61 dated March 25, 2026. The price target is an average of many targets provided by analysts. The lates
- Fintel · Mar 27, 1:33 PM EDTEquillium (EQ) Price Target Increased by 120.00% to 5.61The average one-year price target for Equillium (NasdaqCM:EQ) has been revised to $5.61 / share. This is an increase of 120.00% from the prior estimate of $2.55 dated February 21, 2026. The price target is an average of many targets provided by analysts. The l
- Fintel · Mar 13, 7:06 PM EDTRoth Capital Initiates Coverage of Equillium (EQ) with Buy RecommendationFintel reports that on March 13, 2026, Roth Capital initiated coverage of Equillium (NasdaqCM:EQ) with a Buy recommendation. Analyst Price Forecast Suggests 3.45% Upside
- Zacks · Nov 20, 7:30 AM ESTThe Zacks Analyst Blog Highlights MS, VOO, SPY, IVV, SPYM, RSP, EQ and EQWLMS sees U.S. equities outpacing global markets into 2026, lifting its S&P 500 outlook and spotlighting ETFs poised to benefit.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Equillium, Inc. from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.